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Summary A study was made of the prognostic value of measurements of pretreatment serum marker levels in
patients with carcinoma of the uterine cervix undergoing radiotherapy. The markers studied were carcinoma
antigen 125 (CA125), squamous cell carcinoma antigen (SCC) and tissue polypeptide antigen (TPA). The levels
of all three markers increased with disease stage. In a univariate analysis stratifying patients according to
either median values or cut-off levels representing the top of the normal range, pretreatment levels predicted
patient survival (follow-up times 1-4 years). In a multivariate analysis, disease stage was the most important
prognostic variable and, after allowing for stage, only CA125 was a significant independent predictor of
treatment outcome. These data suggest that, in carcinoma of the cervix treated with radiotherapy, pretreat-
ment measurements of CA125, but not SCC and TPA, may have a role to play in defining prognosis.
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Several reports have suggested that serum estimations of a
number of tumour markers may be useful in assessing
patients with cervical cancer. Carcinoma antigen 125
(CA125), squamous cell carcinoma antigen (SCC) and tissue
polypeptide antigen (TPA) have all been identified, in
elevated levels, in association with cervical carcinoma (Kato
and Torigoe, 1977; Duk et al., 1989; Avall-Lundqvist et al.,
1989, 1992). Pretreatment serum concentrations reflect stage
of disease (Avall-Lundqvist et al., 1992) and have been
shown to have prognostic significance (Maiman et al., 1989;
Duk et al., 1990; Avall-Lundqvist et al., 1992; Ngan et al.,
1994).
In published studies evaluating the predictive potential of
serum marker levels in carcinoma of the cervix, treatment has
been variously by surgery, radiotherapy and chemotherapy,
given either alone or in combination. Therefore, the present
work was set up in order to investigate further the prognostic
significance of the three serum tumour markers in carcinoma
of the cervix treated more consistently, predominantly by
radiotherapy alone. In addition, as few studies have
evaluated the independence of predicting disease outcome
after allowing for stage of disease (Avall-Lundqvist et al.,
1992), multivariate analyses were carried out to determine the
independence of serum marker prognosis.
Materials and methods
Patients
Peripheral blood samples were obtained from patients who
had been referred to the Christie Hospital for treatment for
invasive primary carcinoma of the uterine cervix between
June 1990 and September 1993. Informed consent was
obtained from all patients. During examination under anaes-
thetic, a biopsy of the tumour was taken for independent
assessment of diagnosis and histological grading. Clinical
staging, according to the FIGO classification, of the patients
was performed during the examination. All the patients were
treated according to strict protocols. Only patients receiving
radical treatment (i.e. with curative intent) were included in
the analyses with patient outcome. The majority of these
received radiotherapy alone as described previously (West et
al., 1993). A small number were treated with curative intent
with radiotherapy plus surgery (4) or chemotherapy (11).
Twenty patients received palliative radiotherapy only and
treatment follow-up was not obtained for 20 patients.
Serum marker analysis
Peripheral blood samples were taken from the patients on the
day before treatment with radiotherapy. These were sep-
arated as described elsewhere (Elyan et al., 1993), coded and
the serum stored at -80°C. All analyses were performed
blind. The assays were carried out using commercially
available kits. CA125 radioimmunoassay kits were purchased
from CIS (UK) (High Wycombe, UK). SCC concentrations
were estimated using the Abbott SCC RIABEAD (Abbott
Laboratories, Chicago, II, USA) and TPA concentrations
using PROLIFIGEN TPA IRMA (AB Sangtec Medical,
Bromma, Sweden). The manufacturer's recommended proce-
dures were followed throughout.
Data analysis
As values for all three serum markers did not appear to be
normally distributed, the Mann-Whitney U-test was used to
test for the level of significance of differences between data
sets. Regression analysis was used to look for correlations
between factors. The probabilities of overall patient survival,
locoregional control and metastasis-free survival were deter-
mined using log-rank analysis, with the continuous variables
grouped into two bands, either above and below the median
values or using a cut-off defined as the top of the normal
range (as commonly used in the literature). Multivariate Cox
analysis was used to test for independence from stage. A
significance level of 0.05 was used throughout.
Results
Data are summarised in Tables I-III. Mean values with
standard deviations for CA125, SCC and TPA were
37 ±86 U ml-', 10 ± 19 ng ml ' and 127 ±163 U ml[' resp-
ectively. A check was made of the reproducibility of the three
diagnostic tests. Triplicate analyses carried out on 40 samples
yielded a mean coefficient of variation (CV) of 8% intra-
assay variability for all three markers. This experimental
error was considerably smaller than the inter-individual
variability, which gave CVs of 232%, 190% and 128% for
CA125, SCC and TPA respectively.
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Table I Serum CA125 levels in relation to disease stage
Stage of Mean ± s.d. Median Range Elevate&
disease n (Uml-') (Uml-') (Uml-') P* levels (%)
All 158 37 86 17 0-734 22
I 41 17 16 12 0-69 9
II 56 26 20 17 3-175 0.035 19
III 48 68 ±43 23 4-734 0.002 35
IV 10 38 27 20 10-154 0.085 25
*Denotes significance for differences between stage I and other disease stages. aThe
percentage ofpatients with marker levels above 35 Uml-'. II vs III P=0.09; II vs IV P=0.49;
III vs IV P=0.89.
Table II Serum SCC levels in relation to disease stage
Stage of Mean ± s.d. Median Range Elevated?
disease n (ngml-') (ngml-') (ngml-') P* levels (%)
All 166 10± 19 3.0 0-140 51
I 46 3.8 ± 2.0 0.6 0-64.9 22
II 59 5.8 ± 8.2 3.0 0-41.0 0.0007 54
III 48 18.0 ± 26.8 7.6 0.2-140.2 0.0001 76
IV 10 24.1 ± 19.8 13.2 0.3-82.5 0.0011 88
*Denotes significance for differences between stage I and other disease stages. aThe
percentage of patients with marker levels above 2.5 ng ml-'. II vs III P=0.0003; II vs IV
P=0.012; III vs IV P=0.51.
Table III Serum TPA levels in relation to disease stage
Stage of Mean ± s.d. Median Range Elevated'
disease n (Uml-') (Uml-') (Uml-') P* levels (%)
All 166 127± 163 69 14-1145 37
I 41 17 16 12 15-1145 21
II 56 26 20 17 14-388 0.019 41
III 48 68 43 23 24-1132 0.001 55
IV 10 38 ±27 20 32-445 0.007 63
*Denotes significance for differences between stage I and other disease stages. aThe
percentage of patients with marker levels above 10OUml-'. II vs III P=0.004; II vs IV
P=0.097; III vs IV P=0.96.
Table IV Serum marker levels in relation to outcome following treatment by radiotherapy
Status n Mean ± s.d. Median Range P
CA125 (Uml-') A 92 23±25 15 4-175
D 27 97 175 30 3-620 0.015
SCC (ngml-') A 95 7 14 2 0-109
D 28 23 32 10 0-140 0.006
TPA (U ml-') A 95 97 99 66 14-595
D 28 186± 177 113 22-683 0.015
Patientswereeitheraliveandwell (A) ordead ofdisease (D). The follow-up times ranged from
1 to 4 years.
Weak, but significant, correlations were seen between the
levels of the different serum markers. There were, however,
no significant associations between marker levels and either
patient age, disease grade or tumour volume. The levels of
SCC were significantly higher in 120 squamous cells tumours
(11.8 ± 20.8 ngml- 1) compared with ten adenocarcinomas
(0.7 ± 1.0 ngml-'). No differences between tumour types
were seen for either CA125 or TPA. For all serum markers,
levels increased with increasing disease stage (Tables I-III).
A comparison was made between the pretreatment serum
marker levels found in patients who were either alive and
well, or dead of disease following radiotherapy (1 year
minimum follow-up time). Marker levels were significantly
higher in the dead outcome group for all three markers
studies (Table IV). A comparison was also made between the
pretreatment serum marker levels found in patients in rela-
tion to the development of metastatic disease. Patients who
developed metastatic disease had significantly higher pretreat-
ment serum marker levels (Table V).
Using log-rank analysis and stratifying according to
median values (the most objective criteria to use), a study
was made of treatment outcome in terms of either survival
(Figure 1), local control (Figure 2) or metastasis-free survival
(Figure 3). For comparison, the prognostic ability of disease
stage is illustrated for the same series of patients. Survival
levels were significantly higher for patients with low (below
the median) serum marker levels for all three markers
studied. Serum marker levels were poorer at predicting local
control levels compared with metastasis-free survival. A
significant difference in local control was only seen for
CA125 (Figure 2). However, significant differences in
metastasis-free survival were seen for all tumour markers
(Figure 3). For comparative purposes the data were also
analysed using the manufacturer's recommended cut-off
levels i.e. 2.5 ng ml' for SCC, 35 Uml-' for CA125 and
100 U ml-' for TPA. These cut-off levels are commonly used
in the literature. Although the higher cut-off gave slightly
better discrimination, similar results were obtained when the
data were stratified by the two different methods (Table VI).
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Table V Serum marker levels in relation to the development of metastatic disease following
treatment with radiotherapy
Status n Mean ± s.d. Median Range P
CA125 (U ml-')
SCC (ng ml-')
N 97 34± 89
M 23 64±95
N 102 8± 16
M 22 20± 33
16 4-620
41 3-459
2 0-109
10 0-140
TPA (Uml-') N 102 102± 106 67 14-595
M 22 192± 179 119 24-683 0.009
Patients were either metastasis-free (N) or with metastases (M). The follow-up times ranged
from I to 4 years.
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Figure 1 Patient survival in relation to disease stage and serum marker levels following treatment by radiotherapy. The numbers
of individuals studied were 125, 119, 123 and 123 for stage, CA125, SCC and TPA respectively. Follow-up times ranged from 1 to
4 years.
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Figure 2 Local control in relation to disease stage and serum marker levels following radical treatment by radiotherapy. The
numbers of individuals studied were 125, 119, 123 and 123 for stage, CA125, SCC and TPA respectively. Follow-up times ranged
from I to 4 years.
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Figure 3 Metastasis-free survival in relation to disease stage and serum marker levels following radical treatment by radiotherapy.
The numbers of individuals studied were 125, 119, 123 and 123 for stage, CA125, SCC and TPA respectively. Follow-up times
ranged from 1 to 4 years.
TableVI Log-rankanalyses showing theprobability ofapretreatment
variable topredict treatment outcomein termsofeitheroverall survival,
local control and metastasis-free survival
Variable Cut-off Survival Local control Metastases
Stage <0.001 <0.001 <0.001
TPA 69 U ml-' 0.024 0.64 0.02
100 U ml-' 0.005 0.42 0.027
SCC 3.0 ngml-' 0.017 0.065 0.007
2.5 ngml-' 0.005 0.018 0.001
CA125 17 U ml-' 0.014 0.013 0.041
35 U ml-' <0.001 0.006 <0.001
Patients were stratified according to either the median serum marker
levels (upper values) or the manufacturer's recommended cut-offlevels
(lower values). All numbers given are P-values.
prognostic ability of serum marker measurements in relation
to disease stage (Table VII). Using Cox multivariate analysis
disease stage was the most important prognostic variable.
After allowing for stage, only CA125 was a significant
independent predictor of treatment outcome. Similar results
were obtained when the data were analysed using two
different cut-off levels.
Discussion
The serum marker levels found in this study were similar to
those reported elsewhere. For example in 142 patients with
carcinoma of the uterine cervix. Avall-Lundqvist et al. (1992)
reported median values of 21 Uml-', 2ngml-' and
50 U ml-' for CA125, SCC and TPA respectively. Increasing
marker levels with disease stage has also been described by
others (e.g. Brioschi et al., 1991; Avall-Lundqvist et al.,
1992).
Using the manufacturer's recommended cut-off levels of
2.5 ngml-' for SCC, 35Uml-' for CA125 and 100 Uml-'
for TPA, elevated levels were seen in 51%, 22% and 37% of
patients for SCC, CA125 and TPA respectively (Tables
I-III). These values are within the ranges reported by others
using the same cut-off levels e.g. 44-57% for SCC (Duk et
al., 1990; Avall-Lundqvist et al., 1992), 23% for CA125
(Gadducci et al., 1990; Avall-Lundqvist et al., 1992) and
28-47% for TPA (Avall-Lundqvist et al., 1992; Ngan et al.,
1994).
Mean serum concentrations of SCC were 7 and 23 ng ml-'
for patients free and dead of disease respectively. These
values are similar to values reported elsewhere of 6 ng ml-'
for patients with no evidence of disease and 16 ng ml ' for
those with recurrent disease (Maiman et al., 1989). This
study has also confirmed that pretreatment measurements of
the three markers can predict treatment outcome in car-
cinoma of the cervix. This has been reported for CA125
(Duk et al., 1990; Avall-Lundqvist et al., 1992), SCC
(Maiman et al., 1989; Duk et al., 1990; Ngan et al., 1994)
and TPA (Ngan et al., 1994). The larger analysis described
here, however, is the first to show that CA125 is better at
predicting recurrence-free survival whereas SCC and TPA
predict for metastasis-free survival. In addition, studies pub-
lished previously on cervical carcinoma involved treatment
predominantly with surgery plus radiotherapy. Therefore, by
confirming the prognostic significance of serum marker
measurements for patients treated with radiotherapy alone,
this study illustrates the independence of the findings from
mode of treatment.
As reported here and elsewhere serum marker concentra-
tions show a strong stage dependence. It is, therefore, not
surprising to find that after allowing for stage the prognostic
significance of all three markers was either lost or reduced.
Only CA125 was shown to be an independent indicator of
prognosis. This finding contrasts with the results of Avall-
Lundqvist et al. (1992) who showed that both CA125 and
SCC were significantly related to survival, in addition to
stage. Similar levels of adenocarcinomas and squamous cell
carcinomas, and similar follow-up times were found in both
studies. Therefore, the disparate findings may be related to
either differences in treatment methods, i.e. radiotherapy
alone (this study) or predominantly surgery plus radio-
therapy (Avall-Lundqvist et al., 1992) or differences in the
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Table VII Cox multivariate analyses showing the relative risk (RR) for survival,
local recurrence-free survival and metastasis-free survival
Survival Local control Metastasis-free
Variable RR P RR P RR P
Stage vs I
II 2.5 <0.001 2.1 0.005 3.7 0.001
III 6.9 6.0 5.3
IV 15.2 9.1 22.9
CA125 2.3 0.041 2.0 0.017 NS
Stage vs I
II 2.6 0.003 2.4 0.002 3.1 0.005
III 5.9 6.9 2.9
IV 11.4 10.4 18.3
CA125 3.1 0.009 NS 8.4 <0.001
Both the median (upper half) and the top ofthe normal range (lower half) were
used as cut-off values.
division of patients between disease stages with 28%, 36%
and 29% of patients having stage I, II and III disease (this
study) compared with 50%, 25% and 19% of patients having
stage I, II and III disease (Avall-Lundqvist et al., 1992).
Previous work by us has shown that measurements of
tumour intrinsic radiosensitivity (assessed as surviving frac-
tion at 2 Gy, SF2) are a good predictor of local control for
carcinoma of the cervix treated with radiotherapy (West et
al., 1993). It will be of interest in the future to combine the
radiosensitivity data with that for the serum markers in
particular to investigate whether SF2 and CA125 might com-
bine to give a better prediction of locoregional failure than
either alone. There is some preliminary evidence to suggest
that SF2 and the serum markers are independent parameters.
For 53 of the tumours studied in this work, SF2 values were
obtained. There were no correlations between SF2 values and
any of the marker levels (P> 0.20 for all). Tumour radiosen-
sitivity data are still being accrued and a multivariate
analysis will be carried out in the future.
In summary, this work has confirmed the prognostic
significance of pretreatment measurements of serum markers
in patients with cancer of the cervix. However, the study has
shown that, after allowing for stage, their influence on treat-
ment outcome is either lost or reduced and only CA125
appears to have any value as a pretreatment prognostic
variable. In the future it will be of interest to evaluate CA125
alongside measurements of tumour intrinsic radiosensitivity.
This will determine whether combinations of SF2 and CA125
can improve the prediction of treatment outcome already
reported for SF2 alone in carcinoma of the cervix undergoing
radiotherapy.
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